We are pleased to announce the first trans-septal clinical trial implant with our proprietary Saturn Transcatheter Mitral Valve. Excellent hemodynamic results are reported for the patient, a 79 year old female suffering from severe mixed (degenerative and functional) mitral regurgitation. The Trans-Septal TMVR procedure was performed as part of the on-going European clinical trial, the CASSINI-EU study, on May 8, 2024 at Santaros Klinikos University Hospital in Vilnius, Lithuania with the Heart Team of Kęstutis Ručinskas, MD; Giedrius Davidavičius, MD; Agnė Drąsutienė, MD; Vilhelmas Bajoras, MD; supported by Torsten Vahl, MD; Lauren Ranard, MD; Paolo Denti, MD; and Stefano Stella, MD.

“Overall, this important case demonstrates that the Saturn valve can be successfully implanted with either retrograde or antegrade approaches. It is exciting to add trans-septal delivery and begin to expand the clinical experience for the Saturn valve beyond the initial trans-apical study, now in long-term follow-up. I continue to believe that Saturn will become a valuable new therapy with fewer anatomical exclusions than other technologies, with the potential to treat a wider range of patients,” said Dr. Paolo Denti who is the Principal Investigator for the CASSINI-EU study.

Read full press release below.